Truist Financial Initiates Coverage on Perspective Therapeutics (NYSE:CATX)

Truist Financial assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $21.00 price target on the stock. Truist Financial’s price target points to a potential upside of 71.29% from the company’s previous close.

CATX has been the topic of a number of other reports. Oppenheimer cut their price target on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Finally, Bank of America began coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.00.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $12.26 on Wednesday. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05. The firm’s 50 day moving average is $13.81.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. On average, equities analysts expect that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new position in Perspective Therapeutics in the second quarter worth $118,000. The Manufacturers Life Insurance Company acquired a new position in shares of Perspective Therapeutics during the second quarter worth $188,000. ZWJ Investment Counsel Inc. purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at $26,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics in the 1st quarter worth $40,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.